Cowen Reiterates Neutral Following Hortonworks (HDP) Q1 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Cowen Reiterates Neutral Following Hortonworks (HDP) Q1 Results
May 12, 2015 6:10 PM EDT
Fibrocell Science, Inc., (Nasdaq: FCSC) 18% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for Fibrocell's lead orphan gene-therapy drug candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The rare pediatric disease designation augments the Orphan Drug designation granted by the FDA and announced by Fibrocell in June 2014 for FCX-007 to treat dystrophic epidermolysis bullosa (DEB), which includes RDEB.
Orexigen Therapeutics (NASDAQ: OREX) 14.8% LOWER;... More
May 12, 2015 4:02 PM EDT
Hortonworks (NASDAQ: HDP) reported Q1 EPS of ($0.77), $0.09 better than the analyst estimate of ($0.86). Revenue for the quarter came in at $22 million versus the consensus estimate of $18.2 million.
For earnings history and earnings-related data on Hortonworks (HDP) click here.
...
More
